Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with Temozolomide and Radiation in Newly Diagnosed Glioblastoma
NCT04216329Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose of Selinexor at 7 weeks. Started Jul 2020; status: completed.
02
Drugs
selinexor
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT04216329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216329.